Huntsman Cancer Institute at the University of Utah | Strategic Alliance Partners

Huntsman Cancer Institute at the University of Utah is a nationally recognized research center and treatment hospital in Salt Lake City. We serve patients with all types of cancer, who come from throughout the Mountain West, including Utah and parts of Idaho, Montana, Nevada, and Wyoming.
Our doctors and scientists include world-renowned experts dedicated to the highest quality standards and driven by the commitment to improve the lives of people affected by cancer.

Connect with us:

Latest from Huntsman Cancer Institute at the University of Utah

Patel Provides Insight Into Post-Transplant Complications in Myeloid Disorders

September 22, 2022

Dr Patel discusses post-transplant complications in myeloid disorders, the prevalence of these complications, and the most common ones that may arise, including primary disease relapse, graft-vs-host disease, infection, organ toxicity, persistent cytopenias, and immunosuppression.

Orteronel Plus ADT Misses OS End Point in Metastatic Hormone-Sensitive Prostate Cancer

May 20, 2022

The addition of orteronel to androgen deprivation therapy vs bicalutamide improved progression-free survival and prostate-specific antigen response in patients with metastatic hormone-sensitive prostate cancer, but missed the primary end point of overall survival in the phase 2 SWOG-1216 trial.

Biomarker Testing Will Fuel Next Wave of Treatment Innovations in Breast Cancer

May 01, 2022

Christos Vaklavas, MD, discusses the increasing emphasis on investigating tumor biology in breast cancer, plus the evolving treatment landscapes in HER2-positive breast cancer, hormone receptor–positive, HER2-negative breast cancer, and triple-negative breast cancer.

The Evolving Role of Prognostic Markers for CLL in the Era of Novel Agents

December 03, 2021

Deborah M. Stephens, DO, discusses her approach to treating a patients with chronic lymphocytic leukemia, how CAR T-cell therapy may fit into the treatment paradigm, and the numerous trials that have shown promise in this space.

Atezolizumab/Cabozantinib Displays Promise in High-Risk mCRPC

October 12, 2021

The combination of atezolizumab and cabozantinib elicited encouraging responses, marked by an unprecedented disease control rate, in previously treated patients with locally advanced or metastatic castration-resistant prostate cancer, but most strikingly in patients with high-risk features.